AMLX

Amylyx reported a net loss of $41.3 million in Q1 2026, missing the consensus EPS estimate, leading to a slight stock price decline. The pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH completed enrollment in late March 2026, with top-line data anticipated in Q3 2026. Amylyx launched a U.S. Expanded Access Program for adults with post-bariatric hypoglycemia in May 2026. Several analysts have issued reports and updated price targets for AMLX. The decision to withdraw AMX0035 (Relyvrio/Albrioza) for ALS from the U.S. and Canadian markets in April 2024 had a significant and lasting impact on the stock price. Amylyx ended Q1 2026 with $279.8 million in cash and marketable securities, expected to fund operations into 2028.